• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Jürgen Dinger

Senior Consultant

Jürgen Dinger is a former Managing Director of ZEG Berlin.  An accomplished epidemiologist he has published extensively on the topics of pharmacoepidemiology, active surveillance studies and the challenges associated with epidemiological bias in observational studies. He continues to serve as Prinicipal Investigator for two long-running ZEG Berlin studies and acts as an external consultant for complex epidemiological queries.

  • share 
  • tweet 
  • share 
  • share 

Publications

Dinger Jürgen, Heinemann Klaas, Moehner Sabine, Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: Results from the extended INAS-SCORE study. Frontiers in Women's Health. 2020; Vol. 5: 1-8. 10.15761/FWH.1000178.
Download PDF: Jürgen-et-al.-2020_Results-from-the-extended-INAS-SCORE-study.pdf
Dinger Jürgen, COCs containing dienogest and 30 μg ethinylestradiol may carry a higher VTE risk compared to corresponding preparations with levonorgestrel: A meta-analysis of four large cohort studies. Frontiers in Women's Health. 2020; Vol. 5: 1-6. 10.15761/FWH.1000175.
Download PDF: Jürgen-2020_COCs-containing-dienogest-and-30-μg-ethinylestradiol.pdf
Barnett Clare, Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Unintended pregnancy rates differ according to combined oral contraceptive – results from the INAS-SCORE study Contraception & Reproductive Health Care. 2019; 1-4. 10.1080/13625187.2019.1629412.
Heinemann Klaas, Dinger Jürgen, Do Minh Thai, Franke Christian, Unintended Pregnancies in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Heinemann Klaas, Hagemann Christine, Do Minh Thai, Franke Christian, Dinger Jürgen, Cardiovascular Safety in Users of Different Combined Oral Contraceptives – Final results from the INAS-SCORE Study Pharmacoepidemiology and Drug Safety. 2017; Volume 26, Issue Supplement S2 Pages 1–674.
Barnett Clare, Hagemann Christine, Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Fertility and combined oral contraceptives - unintended pregnancies and planned pregnancies following oral contraceptive use - results from the INAS-SCORE study Eur J Contracept Reprod health Care. 2016; Oct 17:1-7. 10.1080/13625187.2016.1241991.
Dinger Jürgen, Do Minh Thai, Heinemann Klaas, Impact of Estrogen Type on Cardiovascular Safety of Combined Oral Contraceptives Contraception. 2016; Oct;94(4):328-39. 10.1016/j.contraception.2016.06.010.
Bardenheuer Kristina, Dinger Jürgen, Franke Christian, Hagemann Christine, Moehner Sabine, Unintended pregnancies in users of different combined oral contraceptives - final results from the INAS-SCORE study. Pharmacoepidemiology and Drug Safety. 2015; 24 (S1): 1–587. 10.1002/pds.3838.
Heinemann Klaas, Dinger Jürgen, Baseline risk factors for cardiovascular events: differences between the USA and Russia in a study population of combined oral contraceptives Pharmacoepidemiology and Drug Safety. 2014; Sep; 23(S1): 1-497. 10.1002/pds.3701.
Dinger Jürgen, Bardenheuer Kristina, Heinemann Klaas, Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; Apr; 89(4): 253–63.. 10.1016/j.contraception.2014.01.023.
Dinger Jürgen, Heinemann Klaas, Transatlantic active surveillance of cardiovascular safety (TASC) of an Etonogestrel/Ethinylestradiol-containing vaginal ring. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Bardenheuer Kristina, Dinger Jürgen, Do Minh Thai, Venous thromboemolism in users of a 24-day regimen of a combined oral contraceptive compare to conventional 21-day regimens: final results from the INAS-OC study. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Dinger Jürgen, Nitschmann S, Kardiovaskuläre Auswirkungen hormoneller Kontrazeption Internist. 2013; 54:1520-1522. doi:10.1007/s00108-013-3394-5.
Rabe T (DGGEF) und Albring C(BVF) zusammen mit dem Arbeitskreis "Thrombophilie und Kontrazeption" , Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Koenig K, Merkle E, Mueck A O, Merki G, Egarter C, Sicherheit hormonaler Kontrazeptiva: Diane 35 und deren Generika.. Frauenarzt 54. 2013; Nr.4.
Heinemann Klaas, Dinger Jürgen, Bardenheuer Kristina, The safety of oral contraceptives in adolescents. Pharmacoepidemiology and Drug Safety. 2013; 22(S1) 1-521. 10.1002/pds.3512.
Dinger Jürgen, Heinemann Klaas, Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstetrics & Gynecology. 2013; 122(4): 800 - 808. 10.1097/AOG.0b013e3182a5ec6b.
Download PDF: Cardiovascular_Risk_Associated_With_the_Use_of_an.11.pdf
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and risk of uterine perforations: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S2) 45. DOI 10.1002.
Heinemann Klaas, Assmann Anita, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 365. DOI 10.1002.
Dinger Jürgen, Bardenheuer Kristina, M Kieble, Informationsquellen von seltenen schwerwiegenden Erkrankungen: Arzt oder Patient? . Abstractband der 7. Jahrestagung der Deutschen Gesellschaft für Epidemiologie,. 2012; Sept: 133(P1).
Rabe T, Luxembourg B, Dinger Jürgen, Kontrazeption & Thrombophilie - Eine Stellungnahme der Deutschen Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin (DGGEF) e.V. und des Berufsverbands für Frauenärzte (BVF) e.V. . Journal of Reproductive Medicine and Endocrinology. 2012; Sept:(1):20-63.
Dinger Jürgen, M Kieble, Rare serious adverse events: comparison of patient- and physician-reported outcomes. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 732. DOI 10.1002.
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Thrombophilie und/oder Z. n. Thromboembolie: Auswahl der richtigen Kontrazeption - Teil 2: Vorgehen bei Risikogruppen. . Gyne Fachzeitschrift für den Arzt der Frau. 2012; Jan;32 Jahrgang.
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Thrombophilie und/oder Z. n. Thromboembolie: Auswahl der richtigen Kontrazeption - Teil 3: Vorgehen bei Risikogruppen. . Gyne Fachzeitschrift für den Arzt der Frau. 2012; Apr;33 Jahrgang.
Bardenheuer Kristina, Dinger Jürgen, VTE risk in users of combined oral contraceptives: impact of a 24-Day regimen containing drospirenone. Pharmacoepidemiology and Drug Safety. 2012; Aug; 21(S3) 361. DOI 10.1002.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Complications associated with unintended pregnancies under IUD use: results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 125.
Dinger Jürgen, EURAS-HRT: cardiovascular and other outcomes - international menopause society. The Journal of Adult Women`s Health & Medicine. 2011; Vol. 14 Supplement 1: 214.
Barnett Clare, Heinemann Klaas, Dinger Jürgen, Intrauterine devices and the risk of uterine perforation: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 233.
Dinger Jürgen, Assmann Anita, Oral contraceptives and the risk of VTE: reanalysis of the EURAS/LASS study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 74.
Heinemann Klaas, Barnett Clare, Dinger Jürgen, Risk factors for uterine perforations during IUD insertion: interim results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 138.
Dinger Jürgen, Bardenheuer Kristina, Franke Christian, The risk of VTE in users of a 24-day regimen of a combined oral contraceptive compared to conventional 21-day OC regimes: results from the INAS-OC study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 131.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: final results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 181.
Dinger Jürgen, Franke Christian, Use of hormonal contraceptives in europe and in the USA: comparative data from the TASC study. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 182.
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Contraception and thrombophilia - a statement from the german society for gynecological endocrinology and reproductive medicine (DGGEF e.V.) and the professional association of german gynaecologists. J Reproduktionsmed Endokrinol. 2011; 8 (Special Issue 1): 126-167.
Dinger Jürgen, Bardenheuer Kristina, Do Minh Thai, Dose of estrogen and contraceptive failure rates of combined oral contraceptives. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 75.
Rabe T, Goeckenjan M, Ahrendt H-J, Crosignani PG, Dinger Jürgen, Mueck A O, Lohr PA, Creinin MD, Sabatini R, Strowitzki T, Oral contraceptive pills: combinations, dosages and the rational behind 50 years of oral hormonal contraceptive development. J Reproduktionsmed Endokrinol. 2011; 8 (Special Issue 1): 33-104.
Bardenheuer Kristina, Dinger Jürgen, Leddin Janko, Reasons for oral contraceptives use in adolescents and adults in europe. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 118.
Dinger Jürgen, Bardenheuer Kristina, Assmann Anita, Safety and effectiveness of oral contraceptives in obese women. Pharmacoepidemiology and Drug Safety. 2011; Aug: 20(S1) 15.
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Mueck A O, Albring C, Thrombophilie und/oder Z. n. Thromboembolie: Auswahl der richtigen Kontrazeption - Teil 1: Vorgehen bei Risikogruppen. . Gyne Fachzeitschrift für den Arzt der Frau,. 2011; Dec;32 Jahrgang.
Bardenheuer Kristina, Dinger Jürgen, Franke Christian, Impact of obesity on the safety and effectiveness of oral contraceptives. 56. GMDS-Jahrestagung und 6. DGEpi-Jahrestagung, German Medical Science GMS Publishing House. 2011; Doc11gmds331..
Rabe T, Luxembourg B, Ludwig M, Dinger Jürgen, Bauersachs R, Rott H, Albring C, Risikofaktor Reisethrombose, Umgang mit hormonalen Kontrazeptiva & Indikation zur Thrombophiliediagnostik gyne. Fachzeitschrift für den Arzt der Frau. 2011; 04/2011; 25-29.
Dinger Jürgen, Do Minh Thai, Bardenheuer Kristina, Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstetrics and Gynecology. 2011; 117:33-40.
Dinger Jürgen, Bardenheuer Kristina, Breast cancer risk associated with the use of levonorgestrel-containing intrauterine devices compared to copper intrauterine devices. Eur J Contracept Reprod Health Care. 2010; S1:46-47.
Dinger Jürgen, Do Minh Thai, Early use effects on the risk of venous thromboembolism after initiation of oral contraceptive use. Eur J Contracept Reprod Health Care. 2010; 15;S1:43.
Dinger Jürgen, Assmann Anita, Long-term active surveillance study for oral contraceptives (LASS): Impact of oral contraceptive use on the start of antihypertensive treatment. Pharmacoepidemiology and Drug Safety. 2010; 19:S232.
Dinger Jürgen, Assmann Anita, Moehner Sabine, Do Minh Thai, Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care. 2010; 36(3):123-129.
Dinger Jürgen, Assmann Anita, Bardenheuer Kristina, Safety long-term active surveillance study for oral contraceptives (LASS): Results on venous and arterial thromboembolism. Eur J Conctracept Reprod Health Care. 2010; S1:128.
Assmann Anita, Heinemann Klaas, Dinger Jürgen, The safety of oral hormone replacement therapy: Interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2010; 19:S31-32.
Dinger Jürgen, Barnett Clare, Moehner Sabine, Assmann Anita, Unintended pregnancies in women using intrauterine devices: Results from the EURAS-IUD study. Pharmacoepidemiology and Drug Safety. 2010; 19:S242.
Shapiro Sid, Dinger Jürgen, Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies J Fam Plann Reprod Health Care. 2010; 36:33-38. 10.1783/147118910790291037.
Bardenheuer Kristina, Dinger Jürgen, Franke Christian, Sicherheit und effektivität von oralen kontrazeptiva bei jugendlichen. Gesundheitswesen. 2010; 72:624.
Bardenheuer Kristina, Dinger Jürgen, Do Minh Thai, Franke Christian, Leddin Janko, Differences in drug utilization of oral contraceptives in the US and Europe. Pharmacoepidemiology and Drug Safety. 2010; 19:S241.
Bardenheuer Kristina, Dinger Jürgen, Assmann Anita, Heinemann Klaas, Leddin Janko, Drug utilization study on the prescribing indications of oral contraceptives in croatia. Pharmacoepidemiology and Drug Safety. 2010; 19:S55.
Bardenheuer Kristina, Barnett Clare, Dinger Jürgen, Franke Christian, Risk profile and OC utilization patterns of women enrolled in INAS-SCORE. Pharmacoepidemiology and Drug Safety. 2010; 19:S30.
Dinger Jürgen, Bardenheuer Kristina, Assmann Anita, Safety and effectiveness of oral contraceptives in adolescents. Eur J Contracept Reprod Health Care. 2010; 15;S1:81.
Dinger Jürgen, Do Minh Thai, The risk of venous thromboembolism in OC users: time patterns after initiation of treatment. Pharmacoepidemiology and Drug Safety. 2010; 19:S214-215.
Bardenheuer Kristina, Dinger Jürgen, Assmann Anita, Leddin Janko, Unterschiede in der europäischen und US-amerikanischen Studienpopulation am Beispiel INAS-OC. Gesundheitswesen. 2010; 72:624.
Heinemann Lothar A , Dinger Jürgen, Assmann Anita, Do Minh Thai, Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare" Contraception. 2010; May;81(5):401-7. 10.1016/j.contraception.2009.12.014.
Dinger Jürgen, Bardenheuer Kristina, The risk of vaenous thromboembolism in users of a drospirenone-containing oral contraceptive with a 24-day regimen - results from the INAS-OC study. Fertility and Sterility. 2010; 94 suppl 1:S3.
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; Sep;114(3):616-22. 10.1097/AOG.0b013e3181b46f54.
Dinger Jürgen, Bardenheuer Kristina, Assmann Anita, International active surveillance study of women taking oral contraceptives (INAS-OC Study) BMC Medical Research Methodology. 2009; 9: 77.. 10.1186/1471-2288-9-77.
Dinger Jürgen, Cronin Maureen, Schellschmidt Ilka, Do Minh Thai, Westhoff C, Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol. 2009; Sep;201(3):263.e1-9. doi: 10.1016/j.ajog.2009.03.017.
Dinger Jürgen, Oral contraceptives and venous thromboembolism: old questions revisited J Fam Plann Reprod Health Care. 2009; 35:211-213. doi: 10.1783/147118909789587385..
Cronin Maureen, Schellschmidt Ilka, Dinger Jürgen, Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol. 2009; 114(3):616-22. 0.1097/AOG.0b013e3181b46f54.
Dinger Jürgen, Assmann Anita, Altmann Matthias, Contraceptive efficacy of oral contraceptives under real life conditions; the impact of a 24-day regimen on contraceptive effectiveness. Pharmacoepidemiol Drug Saf. 2008; 17: S104.
Assmann Anita, Dinger Jürgen, Filonenko A, Do Minh Thai, Heinemann Lothar A , Impact of severe premenstrual disorders on work, daily life, social relations, and quality of life: preliminary results of a multinational follow-up study. Pharmacoepidemiol Drug Saf. 2008; 17: S116.
Dinger Jürgen, Assmann Anita, Kuehl-Habich D, Oral contraceptives and the risk of arrhythmia: final results from the EURAS-OC study. Pharmacoepidemiology and Drug Safety. 2008; 17: S260.
Dinger Jürgen, Assmann Anita, Kolbeck A, Cardiovascular safety of oral hormone replacement: interim results from the EURAS-HRT study. Pharmacoepidemiol Drug Saf. 2008; 17: S270.
Dinger Jürgen, Assmann Anita, The safety of HRT under real life conditions: interim results from the EURAS HRT study. Gynecol Endocrinol. 2008; 24: S51.
Raff T, Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, The risk of uterine and ovarian cancer for different formulations of hormone therapy (HT). The Open Epidemiology Journal. 2008; 1:17-25.
Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, No increased risk of colon cancer associated with various HRT formulations: a case-control study BMC Cancer. 2007; 7:76. doi:10.1186/1471-2407-7-76.
Heinemann Lothar A , Dinger Jürgen, Range of published estimates of VTE incidence in young women Contraception. 2007; 75: 3328-336.
Dinger Jürgen, Heinemann Lothar A , Kuehl-Habich D, The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance study on Oral Contraceptives (EURAS-OC) based on 142,475 women-years of observation Contraception. 2007; DOI: 10.1016/j.contraception.2006.12.019.
Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, Colon cancer risk and different HRT formulations: a case-control study. BMC Cancer. 2007; 8;7:76.
Dinger Jürgen, Heinemann Lothar A , Westhoff C, Final results from the EURAS study: impact of oral contraception on public health. Obstet Gynecol. 2007; 109(4): 5S.
Dinger Jürgen, Heinemann Lothar A , Westhoff C, First results from the international active surveillance study on oral contraceptives (INAS-OC). Obstet Gynecol. 2007; 109(4): 58S.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , The safety and efficacy of oral contraceptives in teenagers: results from the EURAS-OC study. Pharmacoepidemiology and Drug Safety. 2007; 16: S13.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , Interim results from the international active surveillance study of women taking oral contraceptives (INAS OC). Pharmacoepidemiology and Drug Safety. 2007; 16: S211.
Dinger Jürgen, Assmann Anita, Kuehl-Habich D, The safety of oral hormone replacement therapy under real life conditions: interim results from the EURAS-HRT study. Pharmacoepidemiology and Drug Safety. 2007; 16: S213.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , Design issues in active surveillance studies: experience from the EURAS studies.. Pharmacoepidemiology and Drug Safety. 2007; 16: S253.
Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Women's Health. 2006; 6:13.
Heinemann Lothar A , Moore C, Dinger Jürgen, Stoehr D, Sensitivity as outcome measure of androgen replacement: the AMS scale. Health and Quality of Life Outcomes. 2006; 4:23.
Dinger Jürgen, Zimmermann T, Heinemann Lothar A , Stoehr D, Quality of life and hormone use: new validation results of MRS scale. Health and Quality of Life Outcomes. 2006; 4:32.
Dinger Jürgen, Heinemann Lothar A , Do Minh Thai, Assmann Anita, Thiel C, The risk of gynaecological cancers associated with different HRT formulations. A nested case-control study in the German Cohort Study on Women’s Health. Geburth Frauenheilk. 2006; 66:145-155.
Dinger Jürgen, Heinemann Lothar A , European Active Surveillance Study of Women taking HRT (EURAS-HRT): study protocol BMC Women's Health. 2006; 6:1. DOI: 10.1186/1472-6874-6-1.
Heinemann Lothar A , Dinger Jürgen, Klinische Studien – eine Evidenzfalle?. Frauenarzt. 2006; 47:331-35.l.
Heinemann Lothar A , Assmann Anita, Dinger Jürgen, The risk of venous thromboembolism (VTE) in oral contraceptives: a new lesson. Pharmacoepidemiology and Drug Safety. 2006; 15: S24.
Schellschmidt I, Do Minh Thai, Dinger Jürgen, Factors influencing return to fertility after use of oral contraceptives. Pharmacoepidemiology and Drug Safety. 2006; 15: S25.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , The European active surveillance study on oral contraceptives (EURAS-OC): final results after more than 130,000 WY of observatio. Pharmacoepidemiology and Drug Safety. 2006; 15: S26.
Assmann Anita, Dinger Jürgen, Heinemann Lothar A , European active surveillance of women taking HRT (EURAS-HRT). Pharmacoepidemiology and Drug Safety. 2006; 15: S73.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , International active surveillance study of women taking oral contraceptives (INAS-OC). Pharmacoepidemiology and Drug Safety. 2006; 15: S132.
Dinger Jürgen, Assmann Anita, Heinemann Lothar A , The impact of obesity on the contraceptive reliability of oral contraceptives. Pharmacoepidemiology and Drug Safety. 2006; 15: S140.
Heinemann Lothar A , Dinger Jürgen, The menopause rating scale (MRS) as outcome measure for hormone treatment. Pharmacoepidemiology and Drug Safety. 2006; 14: S44.
Heinemann Lothar A , Dinger Jürgen, Safety of a new oral contraceptive containing drospirenone Drug Safety. 2004; 27(13):1001-18.

sidebar

Executive Team

  • Clare Barnett
  • Karl Pauls
  • Michael Schultze
  • Alfred Pauls
  • Anja Bauerfeind
  • Do Minh Thai
  • Elisabeth Finger
  • Jens A. Lange

Management Board

  • Klaas Heinemann
  • Clare Barnett
  • Marc Pignot
  • Karl Pauls
  • Johanna Poppe

Project Management Team

  • Pauline De Corte
  • Lisa Eggebrecht
  • Maria Cabral
  • Anitha Pitchika
  • Mohammed Dagher

Search

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Diagnostic tools
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.